Synergy Pharmaceuticals Inc. SGYP today announced plans to move
forward this quarter with SP-333, its proprietary next-generation
guanylate cyclase-C (GC-C) agonist, into a phase 2 study for the
treatment of opioid-induced constipation (OIC).
“The start of this trial represents the ongoing progress being made in
the clinical development of our novel GC-C agonist platform in multiple
gastrointestinal indications,” said Dr. Gary S. Jacob, President and
Chief Executive Officer of Synergy Pharmaceuticals Inc. “We recognize a
significant market opportunity for new OIC drug candidates and believe
SP-333 has excellent potential to address the unmet medical needs of
these patients. We look forward to evaluating the potential role of
SP-333 for OIC as part of our
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in